Blockade of Chronic Type I Interferon Signaling to Control Persistent LCMV Infection
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Type I interferons (IFN-I) are critical for antiviral immunity; however, chronic IFN-I signaling is associated with hyperimmune activation and disease progression in persistent infections. We demonstrated in mice that blockade of IFN-I signaling diminished chronic immune activation and immune suppression, restored lymphoid tissue architecture, and increased immune parameters associated with control of virus replication, ultimately facilitating clearance of the persistent infection. The accelerated control of persistent infection induced by blocking IFN-I signaling required CD4 T cells and was associated with enhanced IFN-γ production. Thus, we demonstrated that interfering with chronic IFN-I signaling during persistent infection redirects the immune environment to enable control of infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, during viral infections, chronic type I and II IFN signaling can lead to immune suppression and a failure to clear viral infection.51-53”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [52]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Functional Role of Type I and Type II Interferons in Antiviral Defense
Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453
Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation
Guarda, G., Braun, M., Staehli, F., Tardivel, A., Mattmann, C., Förster, I., Farlik, M., Decker, T., Du Pasquier, R. A., Romero, P., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.006 · Cited by 933
Interleukin-10 determines viral clearance or persistence in vivo
Brooks, D. G., Trifilo, M. J., Edelmann, K. H., Teyton, L., McGavern, D. B., & Oldstone, M. B. A. (2006) · Nature Medicine · doi:10.1038/nm1492 · Cited by 923
Self-citationInterferon signaling and treatment outcome in chronic hepatitis C
Sarasin-Filipowicz, M., Oakeley, E. J., Duong, F. H. T., Christen, V., Terracciano, L., Filipowicz, W., & Heim, M. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707882105 · Cited by 642
Resolution of a chronic viral infection after interleukin-10 receptor blockade
Ejrnaes, M., Filippi, C. M., Martinic, M. M., Ling, E. M., Togher, L. M., Crotty, S., & von Herrath, M. G. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061462 · Cited by 548
Jacquelin, B., Mayau, V., Targat, B., Liovat, A.-S., Kunkel, D., Petitjean, G., Dillies, M.-A., Roques, P., Butor, C., Silvestri, G., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci40093 · Cited by 481
Constitutive Type I Interferon Modulates Homeostatic Balance through Tonic Signaling
Gough, D. J., Messina, N. L., Clarke, C. J. P., Johnstone, R. W., & Levy, D. E. (2012) · Immunity · doi:10.1016/j.immuni.2012.01.011 · Cited by 470
Pathogenic Mechanisms of HIV Disease
Moir, S., Chun, T.-W., & Fauci, A. S. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130254 · Cited by 463
Research works printed but not linked: 2
- Brockman MA Blood 2009 114 346 19365081 PMC2714209 · DOI · Paper page
- 10.1089/jir.2012.0037 · DOI
Cited by
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Regulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3581 · Cited by 3,297
Type I interferons in infectious disease
McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
“Other genes include interferon stimulated genes, which may promote immune suppression through PD-L1 10,11 .”
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055318 · Cited by 1,975
“Administration of anti-IFNAR1 following establishment of T cell exhaustion also enhanced viral control (183, 184), highlighting the complexity of the antiviral versus proexhaustion balance for these cytokines.”
BackgroundThe diverse functions of the PD1 inhibitory pathway
Sharpe, A. H., & Pauken, K. E. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.108 · Cited by 1,971
Tumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A., & Ribas, A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,486
Channappanavar, R., Fehr, A. R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D. K., & Perlman, S. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.01.007 · Cited by 1,419
“Furthermore, during persistent viral infections such as those caused by lymphocytic choriomeningitis virus or SIV, IFN-I promotes chronic immune activation and upregulates the expression of inhibitory molecules such as PD-1 and LAG-3, resulting in impaired T cell responses (Sandler et al., 2014; Teijaro et al., 2013;…”
Overcoming T cell exhaustion in infection and cancer
Pauken, K. E., & Wherry, E. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.008 · Cited by 1,171
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.022 · Cited by 1,216
“The dose and schedule are likely critical and will need optimization, as indiscriminately blocking IFN signaling on host cells can interfere with the generation of anti-tumor (Diamond et al., 2011) and anti-viral responses (Ng et al., 2015; Sandler et al., 2014; Wilson et al., 2013).”
The multifaceted biology of plasmacytoid dendritic cells
Swiecki, M., & Colonna, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3865 · Cited by 1,131
IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation
Ouyang, W., & O’Garra, A. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.020 · Cited by 1,072
Shared and Distinct Functions of Type I and Type III Interferons
Lazear, H. M., Schoggins, J. W., & Diamond, M. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.025 · Cited by 1,138
The unique immunological and microbial aspects of pregnancy
Mor, G., Aldo, P., & Alvero, A. B. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.64 · Cited by 1,041
Resolution of inflammation: a new therapeutic frontier
Fullerton, J. N., & Gilroy, D. W. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.39 · Cited by 937
Tolerance and exhaustion: defining mechanisms of T cell dysfunction
Schietinger, A., & Greenberg, P. D. (2014) · Trends in Immunology · doi:10.1016/j.it.2013.10.001 · Cited by 673
“Furthermore, suppressive cytokines such as IL-10 and transforming growth factor (TGF-β), immune cells including myeloid suppressor cells [81], Foxp3+ CD4+ regulatory T cells [7], and prolonged production of type I interferons (IFN-α/β) that paradoxically up-regulate expression and production of inhibitory molecules, c…”
The dual nature of type I and type II interferons
Lee, A. J., & Ashkar, A. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02061 · Cited by 690
“In chronic LCMV infection, a persistent type I IFN signature prevented BM differentiation and proliferation of conventional DCs (48, 49).”
BackgroundThe TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness
Wu, T., Ji, Y., Moseman, E. A., Xu, H. C., Manglani, M., Kirby, M., Anderson, S. M., Handon, R., Kenyon, E., Elkahloun, A., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aai8593 · Cited by 627
“Cytokines, such as interleukin10 (IL-10) (14) and type I interferon (IFN) (15, 16), also affect T cell exhaustion.”
BackgroundInfluentialAging-induced type I interferon response at the choroid plexus negatively affects brain function
Baruch, K., Deczkowska, A., David, E., Castellano, J. M., Miller, O., Kertser, A., Berkutzki, T., Barnett-Itzhaki, Z., Bezalel, D., Wyss-Coray, T., et al. (2014) · Science · doi:10.1126/science.1252945 · Cited by 615
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Patel, S. A., & Minn, A. J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.007 · Cited by 573
“…in the LCMV model at later times after chronic infection is established can decrease viral titers and improve chronic infection, indicating that chronic IFN signaling contributes to immune suppression and persistent infection (Sandler et al., 2014; Teijaro et al., 2013; Wilson et al., 2013).”
BackgroundInfluentialType I Interferon in the Pathogenesis of Lupus
Crow, M. K. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1002795 · Cited by 561
IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes
Channappanavar, R., Fehr, A. R., Zheng, J., Wohlford-Lenane, C., Abrahante, J. E., Mack, M., Sompallae, R., McCray, P. B., Meyerholz, D. K., & Perlman, S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126363 · Cited by 556
Benci, J. L., Johnson, L. R., Choa, R., Xu, Y., Qiu, J., Zhou, Z., Xu, B., Ye, D., Nathanson, K. L., June, C. H., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.019 · Cited by 541
“In the context of chronic pathogen infection, persistent IFN signaling and ISGs dampen immune responses to prevent immune-mediated pathology while allowing for a host-pathogen stalemate (Cheng et al., 2017; Teijaro et al., 2013; Wilson et al., 2013).”
BackgroundMolecular and Transcriptional Basis of CD4+ T Cell Dysfunction during Chronic Infection
Crawford, A., Angelosanto, J. M., Kao, C., Doering, T. A., Odorizzi, P. M., Barnett, B. E., & Wherry, E. J. (2014) · Immunity · doi:10.1016/j.immuni.2014.01.005 · Cited by 496
Type I Interferon in Chronic Virus Infection and Cancer
Snell, L. M., McGaha, T. L., & Brooks, D. G. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.05.005 · Cited by 500
“This subset skewing likely contributes to the progressive IFN-I-mediated immune dysfunction during chronic infection [11,12] and may also link chronic IFN-I signaling to decreased success of anti-PD-L1 blockade and other checkpoint inhibitor therapies by limiting the progenitor CD8 T cell populations able to respond.”
InfluentialSelf-citationHost STING-dependent MDSC mobilization drives extrinsic radiation resistance
Liang, H., Deng, L., Hou, Y., Meng, X., Huang, X., Rao, E., Zheng, W., Mauceri, H., Mack, M., Xu, M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01566-5 · Cited by 488
Type I and III interferons disrupt lung epithelial repair during recovery from viral infection
Major, J., Crotta, S., Llorian, M., McCabe, T. M., Gad, H. H., Priestnall, S. L., Hartmann, R., & Wack, A. (2020) · Science · doi:10.1126/science.abc2061 · Cited by 503
Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression
Sandler, N. G., Bosinger, S. E., Estes, J. D., Zhu, R. T. R., Tharp, G. K., Boritz, E., Levin, D., Wijeyesinghe, S., Makamdop, K. N., del Prete, G. Q., et al. (2014) · Nature · doi:10.1038/nature13554 · Cited by 461
Regulation of antiviral T cell responses by type I interferons
Crouse, J., Kalinke, U., & Oxenius, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3806 · Cited by 479
Prokhnevska, N., Cardenas, M. A., Valanparambil, R. M., Sobierajska, E., Barwick, B. G., Jansen, C., Reyes Moon, A., Gregorova, P., delBalzo, L., Greenwald, R., et al. (2023) · Immunity · doi:10.1016/j.immuni.2022.12.002 · Cited by 365
Guarding the frontiers: the biology of type III interferons
Wack, A., Terczyńska-Dyla, E., & Hartmann, R. (2015) · Nature Immunology · doi:10.1038/ni.3212 · Cited by 364
“Furthermore, the blockade of adaptive immune responses by excessive production of type I IFN during chronic infection has been described in detail for T cells 80, 81 and to a lesser degree for B cells 71 .”
BackgroundPathogenic potential of interferon αβ in acute influenza infection
Davidson, S., Crotta, S., McCabe, T. M., & Wack, A. (2014) · Nature Communications · doi:10.1038/ncomms4864 · Cited by 369
“…recently been demonstrated to contribute to the establishment and maintenance of chronic lymphocytic choriomeningitis virus infection in mice, where an elevated type I IFN response correlated to increased expression of immunosuppressive genes leading to an impaired adaptive immune response 41,42 .”
Immune responses and immunopathology in acute and chronic viral hepatitis
Shin, E.-C., Sung, P. S., & Park, S.-H. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.69 · Cited by 365
Three decades of messenger RNA vaccine development
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342
Kurachi, M. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00744-5 · Cited by 314
The Roles of Type I Interferon in Bacterial Infection
Boxx, G. M., & Cheng, G. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.05.016 · Cited by 335
“However, sustained expression seems to be detrimental to the clearance of persistent viral infections (Wilson et al., 2013).”
BackgroundSelf-citationT cell exhaustion during persistent viral infections
Kahan, S. M., Wherry, E. J., & Zajac, A. J. (2015) · Virology · doi:10.1016/j.virol.2014.12.033 · Cited by 324
“Studies of chronic LCMV infections have shown that, paradoxically, the number one enemy of many viral infections, IFN-I, enhances CD4 T cell exhaustion and promotes viral persistence, possibly as a tactic for avoiding immunopathology (Teijaro et al., 2013; Wilson et al., 2013).”
BackgroundRegulation of type I interferon signaling in immunity and inflammation: A comprehensive review
Chen, K., Liu, J., & Cao, X. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.03.008 · Cited by 312
Type I Interferons in Autoimmune Disease
Crow, M. K., Olferiev, M., & Kirou, K. A. (2019) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043952 · Cited by 291
“Two studies comparing the pathology induced by two LCMV strains—clone 13 and Armstrong—are particularly notable (103, 104).”
BackgroundBradley, K. C., Finsterbusch, K., Schnepf, D., Crotta, S., Llorian, M., Davidson, S., Fuchs, S. Y., Staeheli, P., & Wack, A. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.105 · Cited by 313
“Induction of the antiviral state is necessary to restrict the damage caused by viral pathogens; however, emerging evidence shows that excessive production of IFN, driven either by pathogen (Bosinger and Utay, 2015; Chen et al., 1999; Li et al., 2018; Stifter and Feng, 2015; Teijaro et al., 2013; Utay and Douek, 2016;…”
BackgroundJain, M. D., Zhao, H., Wang, X., Atkins, R., Menges, M., Reid, K., Spitler, K., Faramand, R., Bachmeier, C., Dean, E. A., et al. (2021) · Blood · doi:10.1182/blood.2020007445 · Cited by 297
The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance
Schönrich, G., & Raftery, M. J. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00207 · Cited by 275
“Blockade or absence of type I IFN signaling during chronic LCMV infection results in reduced PD-L1 expression despite enhanced viral replication (Teijaro et al., 2013; Wilson et al., 2013; Shaabani et al., 2016).”
BackgroundTargeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses
Yang, X., Zhang, X., Fu, M. L., Weichselbaum, R. R., Gajewski, T. F., Guo, Y., & Fu, Y.-X. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.004 · Cited by 269
“Indeed, the action of this cytokine is poorly understood, because it may function as either an immune-activating or immune-suppressing reagent in different disease models (González-Navajas et al., 2012; Teijaro et al., 2013; Wilson et al., 2013).”
BackgroundImmune Responses to HCV and Other Hepatitis Viruses
Park, S.-H., & Rehermann, B. (2014) · Immunity · doi:10.1016/j.immuni.2013.12.010 · Cited by 265
“This is consistent with data in LCMV-infected mice in which blockade of type I IFN signaling increases the frequency and function of virus-specific CD4 T cells (Teijaro et al., 2013; Wilson et al., 2013).”
Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
Minn, A. J., & Wherry, E. J. (2016) · Cell · doi:10.1016/j.cell.2016.03.031 · Cited by 271
“Examples of this dual role for IFN-I come from studies on chronic viral-host interactions (Teijaro et al., 2013; Wilson et al., 2013).”
BackgroundCostimulatory and Coinhibitory Receptor Pathways in Infectious Disease
Attanasio, J., & Wherry, E. J. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.022 · Cited by 256
Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients
Mathew, D., Marmarelis, M. E., Foley, C., Bauml, J. M., Ye, D., Ghinnagow, R., Ngiow, S. F., Klapholz, M., Jun, S., Zhang, Z., et al. (2024) · Science · doi:10.1126/science.adf1329 · Cited by 232
“Blocking the IFN-I receptor (IFNAR1) improves viral control during chronic LCMV infection ( 4 , 5 ), prevents antigen-specific CD8 T cells from becoming terminally exhausted, and preserves theCXCR5 + TCF1 + exhaustedprogenitorsubset ( 6 ).”
BackgroundPTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity
LaFleur, M. W., Nguyen, T. H., Coxe, M. A., Miller, B. C., Yates, K. B., Gillis, J. E., Sen, D. R., Gaudiano, E. F., Al Abosy, R., Freeman, G. J., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0480-4 · Cited by 245
Type I interferons in viral control and immune regulation
Teijaro, J. R. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.01.001 · Cited by 239
Serti, E., Chepa-Lotrea, X., Kim, Y. J., Keane, M., Fryzek, N., Liang, T. J., Ghany, M., & Rehermann, B. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.004 · Cited by 245
“Blocking of the IFNa/b receptor in this model increased the number of NK cells and virus-specific CD4 T cells and restored systemic IFNg levels, thereby inducing LCMV clearance.(26,27) Overall, normalization of NK cell phenotype and function followed a hierarchy.”
Kusnadi, A., Ramírez-Suástegui, C., Fajardo, V., Chee, S. J., Meckiff, B. J., Simon, H., Pelosi, E., Seumois, G., Ay, F., Vijayanand, P., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abe4782 · Cited by 232
“age of the hospitalized patients was 60 (33-82) and 77% were”
BackgroundRegulatory T‐cell homeostasis: steady‐state maintenance and modulation during inflammation
Smigiel, K. S., Srivastava, S., Stolley, J. M., & Campbell, D. J. (2014) · Immunological Reviews · doi:10.1111/imr.12170 · Cited by 222
“For instance, during acute viral infection, IFNs are induced transiently and promote viral clearance, whereas during chronic infection, heightened and prolonged IFN expression promotes viral persistence and immunosuppression (171).”
BackgroundJAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
Zak, J., Pratumchai, I., Marro, B. S., Marquardt, K. L., Zavareh, R. B., Lairson, L. L., Oldstone, M. B. A., Varner, J. A., Hegerova, L., Cao, Q., et al. (2024) · Science · doi:10.1126/science.ade8520 · Cited by 193
SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation
Yan, B., Freiwald, T., Chauss, D., Wang, L., West, E., Mirabelli, C., Zhang, C. J., Nichols, E.-M., Malik, N., Gregory, R., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abg0833 · Cited by 220
Chen, G. M., Chen, C., Das, R. K., Gao, P., Chen, C.-H., Bandyopadhyay, S., Ding, Y.-Y., Uzun, Y., Yu, W., Zhu, Q., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1677 · Cited by 207
“Mouse models of persistent LCMV infection have shown that blockage of type I IFN is associated with improved T-cell responses (33, 46), highlighting the immunosuppressive effect of chronic IFN signaling.”
BackgroundCirculating tumor cells: from new biological insights to clinical practice
Gu, X., Wei, S., & Lv, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01938-6 · Cited by 182
“450,451 Suboptimal type-I IFN signaling triggered by immunogenic cell death (ICD) does not consistently result in effective anticancer immunity.”
BackgroundImmunologic strategies for HIV-1 remission and eradication
Barouch, D. H., & Deeks, S. G. (2014) · Science · doi:10.1126/science.1255512 · Cited by 211
“In murine models of chronic lymphocytic choriomeningitis virus (LCMV) infection, inhibition of type I interferon leads to decreased immune activation, decreased PD-1/PD-L1 activity, decreased amounts of the immunomodulatory cytokine interleukin (IL)-10, restored lymphoid architecture, improved CD4+ T cell responses, a…”
BackgroundEndogenous Retroelements and the Viral Mimicry Response in Cancer Therapy and Cellular Homeostasis
Chen, R., Ishak, C. A., & De Carvalho, D. D. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0506 · Cited by 205
Penaloza-MacMaster, P., Kamphorst, A. O., Wieland, A., Araki, K., Iyer, S. S., West, E. E., O’Mara, L., Yang, S., Konieczny, B. T., Sharpe, A. H., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20132577 · Cited by 213
“It is important to point out that LCMV cl-13 and other viruses that cause chronic infections are relatively resistant to IFNs (Moskophidis et al., 1994) and IFNs may even have a detrimental effect on the course of the infection (Teijaro et al., 2013; Wilson et al., 2013).”
BackgroundFunctions and regulation of T cell-derived interleukin-10
Neumann, C., Scheffold, A., & Rutz, S. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101344 · Cited by 196
Mayer-Barber, K. D., & Yan, B. (2017) · Cellular & Molecular Immunology · doi:10.1038/cmi.2016.25 · Cited by 213
Opposing Roles of Type I Interferons in Cancer Immunity
Boukhaled, G. M., Harding, S., & Brooks, D. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-031920-093932 · Cited by 191
Self-citationFerrari, C. (2015) · Liver International · doi:10.1111/liv.12749 · Cited by 196
“Interestingly, control of chronic LCMV infection in mice can be obtained by blocking instead of stimulating Type I IFN signalling, because continuous ISG induction can lead to the potentiation of negative regulatory pathways which can facilitate persistence rather than control of the virus (73, 74).”
BackgroundRelative resistance of HIV-1 founder viruses to control by interferon-alpha
Fenton-May, A. E., Dibben, O., Emmerich, T., Ding, H., Pfafferott, K., Aasa-Chapman, M. M., Pellegrino, P., Williams, I., Cohen, M. S., Gao, F., et al. (2013) · Retrovirology · doi:10.1186/1742-4690-10-146 · Cited by 197
“However, chronic production of type 1 IFNs during persistent viral infections can have detrimental effects, driving hyperimmune activation and impairing control of ongoing viral replication [14,15].”
BackgroundDisease-Promoting Effects of Type I Interferons in Viral, Bacterial, and Coinfections
Davidson, S., Maini, M. K., & Wack, A. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0227 · Cited by 196
“…HIV must strike a delicate balance where it suppresses IFN-ab production by infected cells to minimize the antiviral response, yet still stimulate some type I IFN secretion from pDCs to drive inflammation and attract CD4 + T cells, thereby creating conditions to favor its own replication.”
BackgroundTargeting type I interferon–mediated activation restores immune function in chronic HIV infection
Zhen, A., Rezek, V., Youn, C., Lam, B., Chang, N., Rick, J., Carrillo, M., Martin, H., Kasparian, S., Syed, P., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci89488 · Cited by 187
“A treatment course of 1 week was chosen because it has been shown to effectively target IFN-I signaling in LCMV-infected mice (5).”
BackgroundMethodSelf-citationImmunomodulatory and antitumor effects of type I interferons and their application in cancer therapy
Medrano, R. F. V., Hunger, A., Mendonça, S. A., Barbuto, J. A. M., & Strauss, B. E. (2017) · Oncotarget · doi:10.18632/oncotarget.19531 · Cited by 182
“In the first work, it was shown that genetic or antibody mediated blockade of IFN-α signaling prior to infection leads to increased viral replication and loss of infection control, thus confirming the antiviral role of IFN-α [181].”
BackgroundTargeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection
Gehring, A. J., & Protzer, U. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.10.032 · Cited by 185
Type I Interferon Responses Drive Intrahepatic T Cells to Promote Metabolic Syndrome
Ghazarian, M., Revelo, X. S., Nøhr, M. K., Luck, H., Zeng, K., Lei, H., Tsai, S., Schroer, S. A., Park, Y. J., Chng, M. H. Y., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aai7616 · Cited by 190
“Moreover, long-standing IFN-I signaling is associated with immune exhaustion in models of persistent viral infection (50).”
BackgroundBlocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs
Cheng, L., Ma, J., Li, J., Li, D., Li, G., Li, F., Zhang, Q., Yu, H., Yasui, F., Ye, C., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci90745 · Cited by 176
“Our results agree with recent findings showing that persistent IFN-I signaling plays a detrimental role during chronic lymphocytic choriomeningitis virus infection and that blockade of IFN-I signaling by IFNAR antibody could reverse T cell exhaustion and enhance antiviral immune response (3, 4).”
BackgroundMethodResultAli, S., Mann-Nüttel, R., Schulze, A., Richter, L., Alferink, J., & Scheu, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00778 · Cited by 172
“Similar to LCMV, Mycobacteria, or Listeria infections (153, 156, 185), it is thought that early robust production of type I IFN in the first 24 h is essential to induce protective innate and adaptive immunity against Plasmodium, while late production of type I IFN impairs host anti-malaria immune responses by inductio…”
Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation
Stewart, C. A., Metheny, H., Iida, N., Smith, L., Hanson, M., Steinhagen, F., Leighty, R. M., Roers, A., Karp, C. L., Müller, W., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65180 · Cited by 173
“Recently, it has been shown that type I IFN contributes to persistent viral infectious by inducing IL-10 production in CD4 + T cells and thus damping the antiviral immune response (79, 80).”
Self-citationType-I Interferon Responses: From Friend to Foe in the Battle against Chronic Viral Infection
Murira, A., & Lamarre, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00609 · Cited by 173
“The deleterious effect of IFN-I responses has been brought into sharper focus more recently by two independent studies using a chronic (LCMV-Clone 13) versus acute (LCMV-Armstrong) infection model, which revealed that viral persistence was diminished by in vivo IFNAR blockade (2, 3).”
BackgroundResultSumida, T. S., Dulberg, S., Schupp, J. C., Lincoln, M. R., Stillwell, H. A., Axisa, P.-P., Comi, M., Unterman, A., Kaminski, N., Madi, A., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01152-y · Cited by 164
“Notably, continuous exposure to IFN-I is implicated to promote T cell exhaustion which is marked by aberrant expression of co-inhibitory receptors (i.e., PD-1, TIM-3, LAG-3, and TIGIT) in chronic viral infection and cancer 12, 13, 14, 15, 16 .”
Rehermann, B., & Bertoletti, A. (2015) · Hepatology · doi:10.1002/hep.27323 · Cited by 168
“This is supported by the experience that a sustained virological response (SVR) after IFN-based therapy is durable in more than 97% of patients.75 Over the past three decades, treatment regimens have evolved from IFN-a to PegIFN-a/ribavirin combination therapy,76 to inclusion of the first protease inhibitors and, most…”
BackgroundInfluentialBlockade of Interferon Beta, but Not Interferon Alpha, Signaling Controls Persistent Viral Infection
Ng, C. T., Sullivan, B. M., Teijaro, J. R., Lee, A. M., Welch, M., Rice, S., Sheehan, K. C. F., Schreiber, R. D., & Oldstone, M. B. A. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.04.005 · Cited by 172
“Although IFN-Is have generally been thought to be beneficial to the immune response against microbial infections, recent research has shown that IFN-I signaling may be detrimental in several pathogenic infections (Davidson et al., 2014; Harris et al., 2010; Mayer-Barber et al., 2014; Teijaro et al., 2013; Teles et al.…”
InfluentialSrivastava, S., Koch, M. A., Pepper, M., & Campbell, D. J. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131556 · Cited by 162
Type I interferon signaling, regulation and gene stimulation in chronic virus infection
Lukhele, S., Boukhaled, G. M., & Brooks, D. G. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.05.001 · Cited by 165
“However, in persistent infections, this beneficial, heightened antiviral response is short-lived as the systemic IFN-I burst is reduced to levels observed in naïve hosts, even though the viral burden remains elevated (7, 118).”
BackgroundResultInfluentialSelf-citationResolution of acute inflammation bridges the gap between innate and adaptive immunity
Newson, J., Stables, M., Karra, E., Arce-Vargas, F., Quezada, S., Motwani, M., Mack, M., Yona, S., Audzevich, T., & Gilroy, D. W. (2014) · Blood · doi:10.1182/blood-2014-03-562710 · Cited by 160
“Proinflammatory cytokines, such as interferon (IFN) and TNF-a, interfere with antigenspecific T-cell responses(43-45) and clearance of viral and mycobacterial infections in mice.(46,47) Furthermore, inhibition of these cytokines enhances pathogen clearance and resolution of disease, an effect that is dependent on the…”
BackgroundType I interferon pathway in CNS homeostasis and neurological disorders
Blank, T., & Prinz, M. (2017) · Glia · doi:10.1002/glia.23154 · Cited by 165
“syndrome behaves immunologically like a poorly controlled chronic viral infection without the presence of a recognizable virus (Wilson et al., 2013).”
BackgroundSex-Based Differences in HIV Type 1 Pathogenesis
Addo, M. M., & Altfeld, M. (2014) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu175 · Cited by 162
“quences for disease outcome, reflecting the important antiviral activity of IFN-α and IFN-α–induced genes during acute infection [29, 30].”
BackgroundNo Love Lost Between Viruses and Interferons
Fensterl, V., Chattopadhyay, S., & Sen, G. C. (2015) · Annual Review of Virology · doi:10.1146/annurev-virology-100114-055249 · Cited by 182
Zhang, G., Chan, B., Samarina, N., Abere, B., Weidner-Glunde, M., Buch, A., Pich, A., Brinkmann, M. M., & Schulz, T. F. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516812113 · Cited by 161
Innate and Adaptive Immune Regulation During Chronic Viral Infections
Zuniga, E. I., Macal, M., Lewis, G. M., & Harker, J. A. (2015) · Annual Review of Virology · doi:10.1146/annurev-virology-100114-055226 · Cited by 156
“However, it is important to note that in LCMV, HCV, HIV, and SIV infections, IFN-I or ISG transcripts are persistently detected in total DCs, CD4+ and CD8+ T cells, and/or tissues, albeit at lower amounts than those detected during the peak IFN-I response (7, 10, 12, 25, 26).”
BackgroundGuo, H., König, R., Deng, M., Riess, M., Mo, J., Zhang, L., Petrucelli, A., Yoh, S. M., Barefoot, B., Samo, M., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.03.001 · Cited by 152
“HIV-1 triggered systematic inflammation is known to cause T cell exhaustion, CD4 T cells depletion, and immune deficiency, while adequately inhibiting IFN-I improves anti-viral T cell function during chronic infection (Li et al., 2014; Wilson et al., 2013).”
BackgroundAtkinson, M. A., von Herrath, M., Powers, A. C., & Clare-Salzler, M. (2015) · Diabetes Care · doi:10.2337/dc15-0144 · Cited by 145
Immune evasion by cancer stem cells
Tsuchiya, H., & Shiota, G. (2021) · Regenerative Therapy · doi:10.1016/j.reth.2021.02.006 · Cited by 160
“However, in a mouse model of chronic virus infection, the blockade of the type-I IFN pathway downregulated the immunosuppressive factors IL-10 and PD-L1 and resulted in a substantial reduction in viral titers in the infected animals [164,165].”
BackgroundNKG2A is a NK cell exhaustion checkpoint for HCV persistence
Zhang, C., Wang, X., Li, S.-R., Twelkmeyer, T., Wang, W., Zhang, S.-Y., Wang, S., Chen, J., Jin, X., Wu, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09212-y · Cited by 154
Qiu, J., Xu, B., Ye, D., Ren, D., Wang, S., Benci, J. L., Xu, Y., Ishwaran, H., Beltra, J., Wherry, E. J., et al. (2023) · Nature Cancer · doi:10.1038/s43018-022-00490-y · Cited by 171
Persistent coxsackievirus B infection and pathogenesis of type 1 diabetes mellitus
Nekoua, M. P., Alidjinou, E. K., & Hober, D. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00688-1 · Cited by 161
Dendritic cells in progression and pathology of HIV infection
Manches, O., Frleta, D., & Bhardwaj, N. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.10.003 · Cited by 158
“Blockade of type I IFN signaling helped resolve persistent infection [103, 104].”
BackgroundAlpha and Beta Type 1 Interferon Signaling: Passage for Diverse Biologic Outcomes
Ng, C. T., Mendoza, J. L., Garcia, K. C., & Oldstone, M. B. A. (2016) · Cell · doi:10.1016/j.cell.2015.12.027 · Cited by 136
“Signaling magnitude is also a factor as antibody blockade of IFNAR-1 produces accelerated viral clearance (Teijaro et al., 2013; Wilson et al., 2013), while deletion or mutation of the gene results in the inability to clear the virus in mice and increased susceptibility to infection in humans.”
BackgroundChen, W., Teo, J. M. N., Yau, S. W., Wong, M. Y., Lok, C., Che, C., Javed, A., Huang, Y., Ma, S., & Ling, G. S. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111647 · Cited by 146
Xing, J., Ly, H., & Liang, Y. (2015) · Journal of Virology · doi:10.1128/jvi.03349-14 · Cited by 141
C-Type Lectin-Like Receptors: Head or Tail in Cell Death Immunity
Drouin, M., Coronilla, J. S., & Chiffoleau, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00251 · Cited by 148
“Authors proposed that as prolonged type-I IFN signaling during chronic virus infection facilitates virus persistence by inducing negative immune regulators, CLEC12A inhibition may be clinically beneficial in cases of persistent infection (116, 117).”
BackgroundSTING-Dependent Type I IFN Production Inhibits Cell-Mediated Immunity to Listeria monocytogenes
Archer, K. A., Durack, J., & Portnoy, D. A. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003861 · Cited by 135
“suppressing cell-mediated mechanisms of viral control [47,48].”
Interferon Lambda Genetics and Biology in Regulation of Viral Control
Hemann, E. A., Gale, M., & Savan, R. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01707 · Cited by 142
Foxa3 Induces Goblet Cell Metaplasia and Inhibits Innate Antiviral Immunity
Chen, G., Korfhagen, T. R., Karp, C. L., Impey, S., Xu, Y., Randell, S. H., Kitzmiller, J., Maeda, Y., Haitchi, H. M., Sridharan, A., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201306-1181oc · Cited by 138
“The present findings are consistent with recent studies wherein IFN was required for normal viral clearance during acute infection but suppressed viral responses in the setting of chronic infection (43, 44).”
ResultSelf-citationTsai, H.-F., & Hsu, P. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0341-0 · Cited by 145
“The type I IFNs (IFNα/β) are crucial in innate antiviral effects; however, recent reports demonstrated that type I IFNs signaling paradoxically facilitated viral persistence by enhancing immune suppression during chronic infection, and IFNα/β blockade reversed T cell exhaustion in chronic viral infection [105, 106], A…”
BackgroundNew insights into the resolution of inflammation
Gilroy, D. W., & Maeyer, R. P. H. D. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.05.003 · Cited by 151
Metadata
- Authors
- Wilson, E. B., Yamada, D. H., Elsaesser, H., Herskovitz, J., Deng, J., Cheng, G., Aronow, B. J., Karp, C. L., & Brooks, D. G.
- Affiliations
- University of California, Los Angeles (US)
- Cincinnati Children's Hospital Medical Center (US)
- Corresponding author
- Brooks, David G.
- ORCID
- Venue
- Science
- Published
- 2013-04-12
- Volume
- 340
- Issue
- 6129
- Pages
- 202-207
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3704950
- OpenAlex
- W2049868800
- Cited by
- 709
- References
- 29
- Citations by year
- 2026: 26 · 2025: 37 · 2024: 34 · 2023: 35 · 2022: 35 · 2021: 48 · 2020: 50 · 2019: 50 · 2018: 58 · 2017: 72 · 2016: 87 · 2015: 72 · 2014: 70 · 2013: 34
- FWCI
- 48.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000077)
- National Heart, Lung, and Blood Institute (R01HL108949, HL108949)
- National Institute of Allergy and Infectious Diseases (AI060567, T32AI060567, U01AI082975, R01AI085043, AI082975, R01AI056154, AI085043, R01AI047868, P30AI028697)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P50AR063020)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- type I interferon signaling, chronic infection, lymphocytic choriomeningitis virus, viral persistence, immune activation, immunosuppression, CD4+ T cells, interferon-gamma, antiviral immunity, viral clearance
- MeSH terms
- Animals, Antibodies, Arenaviridae Infections, Dendritic Cells, Immune Tolerance, Interferon Type I, Interferon-gamma, Lymphocytic choriomeningitis virus, Virus Replication, Signal Transduction, CD4-Positive T-Lymphocytes, Cytokines, Interleukin-10, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Mice, Receptor, Interferon alpha-beta, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.